182 related articles for article (PubMed ID: 22524499)
1. Differentiated thyroid carcinoma after 131I-MIBG treatment for neuroblastoma during childhood: description of the first two cases.
van Santen HM; Tytgat GA; van de Wetering MD; van Eck-Smit BL; Hopman SM; van der Steeg AF; Nieveen van Dijkum EJ; van Trotsenburg AS
Thyroid; 2012 Jun; 22(6):643-6. PubMed ID: 22524499
[TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up of the thyroid gland after treatment with 131I-Metaiodobenzylguanidine in children with neuroblastoma: importance of continuous surveillance.
Clement SC; van Eck-Smit BL; van Trotsenburg AS; Kremer LC; Tytgat GA; van Santen HM
Pediatr Blood Cancer; 2013 Nov; 60(11):1833-8. PubMed ID: 23832530
[TBL] [Abstract][Full Text] [Related]
3. Differentiated thyroid carcinoma after iodine-131 metaiodobenzylguanidine treatment for neuroblastoma: assessment of causality.
Teszler CB
Thyroid; 2013 Feb; 23(2):248-9. PubMed ID: 22946503
[No Abstract] [Full Text] [Related]
4. Improved radiation protection of the thyroid gland with thyroxine, methimazole, and potassium iodide during diagnostic and therapeutic use of radiolabeled metaiodobenzylguanidine in children with neuroblastoma.
van Santen HM; de Kraker J; van Eck BL; de Vijlder JJ; Vulsma T
Cancer; 2003 Jul; 98(2):389-96. PubMed ID: 12872361
[TBL] [Abstract][Full Text] [Related]
5. Primary ovarian insufficiency in children after treatment with 131I-metaiodobenzylguanidine for neuroblastoma: report of the first two cases.
Clement SC; Kraal KC; van Eck-Smit BL; van den Bos C; Kremer LC; Tytgat GA; van Santen HM
J Clin Endocrinol Metab; 2014 Jan; 99(1):E112-6. PubMed ID: 24187404
[TBL] [Abstract][Full Text] [Related]
6. Long-term efficacy of current thyroid prophylaxis and future perspectives on thyroid protection during 131I-metaiodobenzylguanidine treatment in children with neuroblastoma.
Clement SC; van Rijn RR; van Eck-Smit BL; van Trotsenburg AS; Caron HN; Tytgat GA; van Santen HM
Eur J Nucl Med Mol Imaging; 2015 Apr; 42(5):706-15. PubMed ID: 25512056
[TBL] [Abstract][Full Text] [Related]
7. Response to teszler.
van Santen HM; Tytgat GA; van de Wetering MD; van Eck-Smit BL; Hopman SM; van der Steeg AF; Nieveen van Dijkum EJ; van Trotsenburg AS
Thyroid; 2013 Feb; 23(2):249. PubMed ID: 23185983
[No Abstract] [Full Text] [Related]
8. [(131)I] and [(125)I] metaiodobenzylguanidine therapy in macroscopic and microscopic tumors: a comparative study in SK-N-SH human neuroblastoma and PC12 rat pheochromocytoma xenografts.
Rutgers M; Buitenhuis CK; van der Valk MA; Hoefnagel CA; Voûte PA; Smets LA
Int J Cancer; 2000 Dec; 90(6):312-25. PubMed ID: 11180134
[TBL] [Abstract][Full Text] [Related]
9. Thyroid function after diagnostic
Clement SC; Tytgat GAM; van Trotsenburg ASP; Kremer LCM; van Santen HM
Ann Nucl Med; 2022 Jun; 36(6):579-585. PubMed ID: 35499668
[TBL] [Abstract][Full Text] [Related]
10. High incidence of thyroid dysfunction despite prophylaxis with potassium iodide during (131)I-meta-iodobenzylguanidine treatment in children with neuroblastoma.
van Santen HM; de Kraker J; van Eck BL; de Vijlder JJ; Vulsma T
Cancer; 2002 Apr; 94(7):2081-9. PubMed ID: 11932913
[TBL] [Abstract][Full Text] [Related]
11. Thyroid and hepatic function after high-dose 131 I-metaiodobenzylguanidine (131 I-MIBG) therapy for neuroblastoma.
Quach A; Ji L; Mishra V; Sznewajs A; Veatch J; Huberty J; Franc B; Sposto R; Groshen S; Wei D; Fitzgerald P; Maris JM; Yanik G; Hawkins RA; Villablanca JG; Matthay KK
Pediatr Blood Cancer; 2011 Feb; 56(2):191-201. PubMed ID: 20830775
[TBL] [Abstract][Full Text] [Related]
12. Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study.
Modak S; Zanzonico P; Carrasquillo JA; Kushner BH; Kramer K; Cheung NK; Larson SM; Pandit-Taskar N
J Nucl Med; 2016 Feb; 57(2):231-7. PubMed ID: 26742708
[TBL] [Abstract][Full Text] [Related]
13. [Thyroid dysfunction due to 131I-metaiodobenzylguanidine in patients with neuroblastoma].
Garrido Magaña E; Silva Estrada JA; Nishimura Meguro E; Rivera Hernández AJ; Zurita Cruz JN
Rev Chil Pediatr; 2020 Jun; 91(3):379-384. PubMed ID: 32730518
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis and treatment of neuroblastoma using metaiodobenzylguanidine.
Edeling CJ; Frederiksen PB; Kamper J; Jeppesen P
Clin Nucl Med; 1987 Aug; 12(8):632-7. PubMed ID: 3665302
[TBL] [Abstract][Full Text] [Related]
15. Endocrine late effects from multi-modality treatment of neuroblastoma.
van Santen HM; de Kraker J; Vulsma T
Eur J Cancer; 2005 Aug; 41(12):1767-74. PubMed ID: 16039114
[TBL] [Abstract][Full Text] [Related]
16. Primary hypothyroidism as a consequence of 131-I-metaiodobenzylguanidine treatment for children with neuroblastoma.
Picco P; Garaventa A; Claudiani F; Gattorno M; De Bernardi B; Borrone C
Cancer; 1995 Nov; 76(9):1662-4. PubMed ID: 8635072
[TBL] [Abstract][Full Text] [Related]
17. [131I-MIBG therapy in the treatment of pheochromocytoma in children--own experiences].
Hasse-Lazar K; Krajewska J; Paliczka-Cieślik E; Jurecka-Lubieniecka B; Michalik B; Handkiewicz-Junak D; Roskosz J; Jarzab B
Endokrynol Pol; 2008; 59(3):235-40. PubMed ID: 18615399
[TBL] [Abstract][Full Text] [Related]
18. Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG).
Fitzgerald PA; Goldsby RE; Huberty JP; Price DC; Hawkins RA; Veatch JJ; Dela Cruz F; Jahan TM; Linker CA; Damon L; Matthay KK
Ann N Y Acad Sci; 2006 Aug; 1073():465-90. PubMed ID: 17102115
[TBL] [Abstract][Full Text] [Related]
19. Thyroidal uptake and radiation dose after repetitive I-131-MIBG treatments: influence of potassium iodide for thyroid blocking.
Brans B; Monsieurs M; Laureys G; Kaufman JM; Thierens H; Dierckx RA
Med Pediatr Oncol; 2002 Jan; 38(1):41-6. PubMed ID: 11835235
[TBL] [Abstract][Full Text] [Related]
20. The role of 131I-MIBG in high-risk neuroblastoma treatment.
Lessig MK
J Pediatr Oncol Nurs; 2009; 26(4):208-16. PubMed ID: 19726792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
